Welcome to our dedicated page for Brandes International ETF news (Ticker: BINV), a resource for investors and traders seeking the latest updates and insights on Brandes International ETF stock.
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company dedicated to discovering and developing novel, first-in-class immuno-modulatory antibodies for cancer therapy. With a robust pipeline featuring five drug candidates in six ongoing clinical programs, BioInvent is at the forefront of cancer immunotherapy research.
One of BioInvent's key assets is its proprietary F.I.R.S.T™ technology platform, which identifies both therapeutic targets and the corresponding antibodies that bind to them. This technology has produced multiple promising drug candidates, fueling BioInvent's own clinical development pipeline and creating valuable licensing and partnership opportunities with top-tier pharmaceutical companies.
Recently, BioInvent has presented encouraging clinical data from various trials. Notably, the Phase 1/2a trial of the FcyRIIB-blocking antibody BI-1607 revealed that the treatment was well-tolerated with no serious adverse events. Additionally, the trial showed stable disease in multiple patients, indicating early signs of efficacy. Another key development includes the combination therapy of BI-1206 with rituximab in patients with relapsed/refractory indolent Non-Hodgkin's Lymphoma (iNHL), which has demonstrated partial and complete responses in clinical trials.
BioInvent’s strategic focus extends to global partnerships. For instance, they have partnered with CASI Pharmaceuticals for the development and commercialization of BI-1206 in China, Hong Kong, Macau, and Taiwan. This collaboration aims to leverage CASI's regulatory and commercial expertise in the Greater China market.
BioInvent also generates revenue from research collaborations, license agreements, and the production of antibodies for third parties through its fully integrated manufacturing unit. The company remains committed to enhancing cancer treatment outcomes with its innovative antibody therapies and is poised to expand its clinical programs significantly.
BioInvent International AB (Nasdaq: BINV) recently highlighted significant advancements in its clinical pipeline during the R&D Day. Key updates include three complete responses for lead drug candidate BI-1206 in non-Hodgkin's lymphoma, with two responses lasting over two years, and successful recruitment in Phase 1/2 trials for BI-1808 and BI-1607. Furthermore, interim results show favorable tolerability for BI-1808 in combination with Keytruda, while BI-1607's IND application has been approved by the FDA, allowing for a trial extension to U.S. centers. The company emphasizes its commitment to transforming cancer therapy.
BioInvent International held an Extraordinary General Meeting on July 12, 2022, where it elected Natalie Berner and Nanna Lüneborg as new Board members. The Board will increase by two members, with annual fees for incoming members continuing as resolved by the previous Annual General Meeting. The fees will be paid on a pro-rata basis according to the duration of their service. The minutes of the meeting will be accessible on the company's website. BioInvent focuses on developing immuno-modulatory antibodies for cancer therapies, with several ongoing clinical trials.
Transgene and BioInvent International AB (BINV) have announced a clinical trial collaboration with MSD to evaluate the oncolytic virus BT-001 in combination with KEYTRUDA® in a Phase I/IIa trial for solid tumors. MSD will supply pembrolizumab for this ongoing trial (NCT04725331), which aims to enhance anti-tumor immune responses. This partnership validates BioInvent's clinical pipeline, which includes three candidates across four trials. The trial is being conducted in Europe and has also been authorized in the US.
Transgene and BioInvent International AB (BINV) have announced positive safety data from the ongoing Phase I/IIa trial of BT-001, an oncolytic virus treatment for solid tumors like melanoma. The initial results show BT-001 is well-tolerated, with signs of anti-tumor activity. Key findings include detectable viral presence within tumors, supporting its treatment mechanism. The trial will continue with 18 patients, and the Safety Review Committee has approved dose escalation. The next phase will test BT-001 in combination with pembrolizumab.
Exelixis has announced a strategic partnership with BioInvent to develop novel antibodies aimed at cancer immunotherapy. This collaboration involves an upfront payment of $25 million from Exelixis for rights to select three targets utilizing BioInvent's advanced screening platform. Exelixis plans to leverage its expertise in antibody engineering to advance these therapies and is focused on expanding its biotherapeutics pipeline. The partnership aims to enhance both companies' capabilities in oncology therapeutics.
FAQ
What is the current stock price of Brandes International ETF (BINV)?
What is BioInvent International AB's main area of focus?
What is the F.I.R.S.T™ technology platform?
What is BI-1607, and what are its recent clinical results?
Who are BioInvent's key partners?
What is BI-1206?
What were the results of the BI-1206 trials?
How does BioInvent generate revenue?
What is the significance of BioInvent's partnership with CASI Pharmaceuticals?
How does BioInvent contribute to cancer treatment?
What are the next steps for BioInvent's clinical programs?
